Topical Products BusinessOTC Pharmaceutical BusinessContract Manufacturing BusinessManufacturing and sales of generic drugs (authorized generics) centered on anticancer agentsContract manufacturing of 100mL drink formulationsAuthorized Generic BusinessResearch, development, manufacturing, and sales of pharmaceuticals, quasi-drugs, and miscellaneous goodsManufacturing and sales of medicated plastersPharmaceuticals and consumer healthcare products
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
66 EVENTS
Since its establishment in 1943, Shinsei Pharmaceutical has developed and supplied topical analgesic anti-inflammatory patches and topical steroid preparations to clinical settings.
Shinsei Pharmaceutical Co., Ltd., predecessor of Okayama Daipō Pharmaceutical, was founded in Shinjuku, Tokyo.
Founded: August 26, 1943 (Showa 18)
June 1963: Daipō Pharmaceutical Industrial Co., Ltd. established
Daipō Pharmaceutical Industrial Co., Ltd. was established.
May 1971: Neopass launched by Daipō Pharmaceutical Industrial Co., Ltd.
Daipō Pharmaceutical Industrial Co., Ltd. began selling 'Neopass'.
June 1975: Headquarters and factory relocated to Ome City, Tokyo.
Moved headquarters and factory to Ome City, Tokyo.
April 1984: Headquarters and factory relocated to Bizen City, Okayama Prefecture (current location).
Moved headquarters and factory to Bizen City, Okayama Prefecture (current location).
September 1990: Daipō Pharmaceutical Industrial Co., Ltd. acquired all shares of Shinsei Pharmaceutical Co., Ltd., becoming a full subsidiary.
Daipō Pharmaceutical Industrial Co., Ltd. acquired all shares of Shinsei Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.
September 1991: Production of Mesaderm® ointment and cream commenced.
Started manufacturing Mesaderm® ointment and Mesaderm® cream.
August 1, 1992: Established (Heisei 4).
August 1992: Company name changed to Okayama Daipō Pharmaceutical Co., Ltd.
Renamed the company to Okayama Daipō Pharmaceutical Co., Ltd.
May 1994: Production of Mesaderm® lotion commenced.
Started manufacturing Mesaderm® lotion.
July 1996: Production of MS cold ship 'Taihou' and MS warm ship 'Taihou' commenced.
Started manufacturing MS Cold Slip 'Taihou' and MS Warm Slip 'Taihou'.
September 1999: Completion of the OTC pharmaceutical dedicated factory at headquarters.
Completed an OTC pharmaceutical dedicated factory at headquarters.
October 1999: Commencement of manufacturing of "Zapp®".
Started manufacturing Zahapp®.
July 2000: Commencement of manufacturing "Sportsman-Ship® Cool".
Started manufacturing Sportsman-Slip® Cool (sold by Nichiban Co., Ltd.).
September 2001: Release of "Roih Warm Ship TM".
Released Royhi Warm Slip™ (sold by Nichiban Co., Ltd.).
April 2005: Implementation of revised Pharmaceutical Affairs Law; selection of manufacturing and sales business.
With the implementation of the revised Pharmaceutical Affairs Law, chose to engage in manufacturing and sales.
March 2006: Acquisition of Type 1 Pharmaceutical Manufacturing and Sales License.
Obtained a license for Class I pharmaceutical manufacturing and sales.
May 2006: Commencement of manufacturing "FernaBiOn® Papp".
Started manufacturing Fernabion® patch.
November 2006: ISO14001 certification obtained.
ISO 14001 certification obtained
December 2006: Patent obtained for adhesive sheet release paper structure.
Patent obtained for adhesive sheet release paper structure
January 2009: Establishment of Otsuka Holdings and consolidation as a consolidated subsidiary.
Establishment of Otsuka Holdings and consolidation as a consolidated subsidiary
September 2012: Release of "Roih Warm Ship TM Ferbinac".
Release of "Roih Warmship TM Ferbinaq" (sold by Nichiban Co., Ltd.)
October 2012: Renewal of "Mesaderm®" (cream, lotion).
Renewal of "Mesaderm®" (cream, lotion)
June 2013: Release of Loxoprofen Sodium Tape "Taihou".
Release of "Loxoprofen Sodium Tape 'Taihou'" (sold by Daipō Pharmaceutical Industrial Co., Ltd.)
January 2017: Release of AG of "Yuzel®" (reduced folic acid formulation) and Holinart tablet "Taihou".
Release of Daipō Pharmaceutical's reduced folic acid formulation "Yuzel®" AG and Holinart tablet "Taihou"
February 2017: Release of "Pure Quick S Ointment".
Release of "Pure Quick S Ointment" (sold by Daipō Pharmaceutical Industrial Co., Ltd.)
June 2017: Release of AG of "TS One®" (metabolism antagonist) with "Swan Taihou®" combination OD tablet.
Release of Daipō Pharmaceutical's metabolic antagonist "TSW1®" AG "Swan Taihou® combined OD tablet"
September 2018: Release of "Roih TM Cream Ferbi".
Release of "Roih TM Cream Ferb" (sold by Nichiban Co., Ltd.)
December 2019: Renamed the selling name of "FernaBiOn® Papp" to "Ferbinac Papp 70mg 'Taihou'" as a general name.
Change of the commercial name of "FernaBiOn® Papp" to the generic name "Ferbinaq Papp 70mg 'Taihou'"
January 2020: Commencement of contract manufacturing of "Thiobita®" drink (100mL) series (seller: Daipō Pharmaceutical Industrial Co., Ltd.).
Start of contract manufacturing for the "Chiovita® Drink (100mL)" series (sold by Daipō Pharmaceutical Industrial Co., Ltd.)
September 2021: Release of AG of "Alokix®" (5-HT3 serotonin receptor antagonist antiemetic) "Parosetron IV" and Parosetron IV infusion bag.
Release of Daipō Pharmaceutical's 5-HT3 (serotonin) receptor antagonist antiemetic "Aroxi®" AG "ParoNocetron IV", "ParoNocetron IV infusion bag"
In January 2025, began in-house sales of ESWANTaihou® OD tablets, Holinart tablets 'Taihou', Parosetron IV injection, and Parosetron IV drip bags.
Start of in-house sales of "Swan Taihou® combined OD tablet", Holinart tablet "Taihou", "ParoNocetron IV", and "ParoNocetron IV infusion bag"
In April 2026, began in-house sales of MS Warm Slip 'Taihou', Mesaderm® ointment 0.1%, Mesaderm® cream 0.1%, and Mesaderm® lotion 0.1%.
Start of in-house sales of MS Warmship "Taihou", "Mesaderm® Ointment 0.1%", "Mesaderm® Cream 0.1%", and "Mesaderm® Lotion 0.1%"
§07
News
18 ARTICLES
Announcement of Natural Symbiosis Site Certification
The natural symbiosis site certification for Okayama Daikou Pharmaceutical's biotope has been announced. The certificate award ceremony, the outlet of the factory's wash and cooling water, and the waterway flowing through the biotope's center are described.
Announcement of Executive Personnel Changes
Okayama Daipō Pharmaceutical Co., Ltd. decided on executive appointments at the regular shareholders' meeting and board of directors meeting held on March 4. Mr. Kenji Yokota was newly appointed as a director overseeing the Pharmaceutical Headquarters, General Affairs Department, and Reliability Assurance Department.
Parosetron formulation, approval of changes to pediatric dosage and administration
Okayama Daiho Pharmaceutical announced that it has obtained approval for pediatric dosage and administration of 'Parosetron IV injection' and 'Parosetron IV infusion bag'.
Notice of Executive Personnel Appointment
Okayama Daipō Pharmaceutical decided on executive personnel at the regular shareholders' meeting and board of directors held on March 6. Mr. Kazu Yoshishige was promoted to President and CEO, and Mr. Fukuichi Ooi was promoted to Executive Director. The Chairman of the Board is Mr. Tatsuya Niki, the Director is Mr. Yōsuke Ishizaki, and the Auditor is Mr. Nobuyuki Hashimoto.
Notice of Discontinuation of New Year's and Summer Greetings
Oka Yamadou Pharmaceutical Co., Ltd. announced that, considering the social situation, it will refrain from sending New Year's cards and summer greetings starting from Reiwa 7 (2025). It requests understanding of the circumstances and apologizes for discontinuing the customary greetings.
Announcement of Executive Appointments
Okayama Daipō Pharmaceutical decided executive appointments at the regular shareholders' meeting and board of directors held on March 6. The executive composition is Chairman Tatsuya Niki, President and CEO Minehisa Katayama, Directors Koichi Kakigi and Yosuke Ishizaki, and Auditor Nobuyuki Hashimoto.
Announcement of Executive Personnel Changes
Okayama Daipō Pharmaceutical decided on executive appointments at the regular shareholders' meeting and board of directors held on March 10. The president and CEO is Mr. Katayama Mine Shino, the executive director is Mr. Hirata Koichi, the director is Mr. Kakigi Kōichi, and the auditor is Mr. Hashimoto Nobuyuki.
Introduce CO2-Free Power
Oka Yamadake Pharmaceutical introduced CO2-free power from China Power to its headquarters and factory area starting in April 2022. This is expected to reduce annual CO2 emissions by about 2,100 tons, roughly 65% of the 2021 level. The company will continue to work on reducing environmental impact and promoting sustainable development in the local community.
Additional Indication Approval for Eswatainho OD Tablets
The oral anticancer agent "Eswatainho OD tablets" has received additional indication approval for adjuvant postoperative chemotherapy in hormone receptor‑positive, HER2‑negative, high‑risk recurrent breast cancer. The same indication has been added to the efficacy and effect section of the package insert.
Obtained Manufacturing and Sales Approval for Palonosetron Preparations
Okayama Daipō Pharmaceutical has obtained manufacturing and sales approval for the 5-HT3 receptor antagonist antiemetic Palonosetron IV injection and Palonosetron IV infusion bag.
§08
Public records
GOV
National Tax Agency basic information9260001021507
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
岡山大鵬薬品株式会社
Trade name (kana)
オカヤマタイホウヤクヒン
Name in English
Corporation type
301
Address
〒705-0024 岡山県備前市久々井字沖1775番地の1
Postal code
7050024
Prefecture code
33
City code
211
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-05-01
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
4847487
METI gBizINFO9260001021507
Source: gBizINFO (Ministry of Economy, Trade and Industry)